ClinicalTrials.gg
CompletedNCT00102310Updated Jan 10, 2018

YM443 in Subjects With Functional Dyspepsia

A Phase 2 interventional study of YM443 in Indigestion and Nausea, sponsored by Astellas Pharma Inc. Completed at 59 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-10.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2004, registered Jan 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Enrollment
3rd of 11
416 · median 282
Started
2004
the only one that year
Phase 2
5 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
3 of 11
Astellas Pharma Inc

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 5 in phase 2, and was the 1st registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.

03

Conditions studied

  • Indigestion
  • Nausea

Browse trials for

Keywords

  • Nausea
  • Indigestion
  • Bloating
  • Functional Dyspepsia
  • Fullness after Meals
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to read and write in English.
  • Written has been obtained.
  • 18-75 years of age on the day the Informed Consent Form is signed.
  • Men or women.
  • Females, not pregnant, lactating or likely to become pregnant.
  • Abdominal ultrasound and/or upper endoscopy findings that are judged as not by the Investigator during Screening or within 4 weeks prior to Screening.
  • Symptoms of FD at Visits 1 and 4 as defined by Rome II criteria.
  • Subjects with a positive H. pylori breath test at Screening may be included in the study.
  • Subjects with pH-metry results at Screening indicative of reflux may be included in the study.
  • , vital signs, and laboratory results that are judged as not clinically significant by the Investigator during Screening.

Exclusion criteria

Exclusion Criteria:

  • Significant renal, hepatic, , cardiovascular, pulmonary, endocrine, metabolic, hematological, neurologic, or gastrointestinal (other than the one being studied) condition.
  • Subjects with diabetes mellitus are to be excluded.
  • Congenital or acquired long syndrome, or uncontrolled arrhythmias.
  • Prior surgery on the luminal GI tract.
  • History of any major psychiatric disorder, current depression or anxiety, alcohol abuse, or substance abuse in the last 2 years.
  • Any evidence or treatment for (with the exception of basal cell carcinoma) within the last 5 years.
  • Confirmed structural gastrointestinal disease.
  • Predominant symptoms of irritable bowel syndrome (IBS) (Rome II criteria) or gastroesophageal reflux disease (GERD) assessed at Visit 1 or 4.
  • Female subjects who are pregnant, lactating, or are likely to become pregnant during the study.
  • Males and females of must be abstinent or agree to use regimens throughout the study.
  • Any history or condition which, in the opinion of the Investigator, makes the subject unsuitable for any of the procedures used during this study or would not allow for safe completion of the study.
  • Known to gastroprokinetics or proton pump inhibitors.
  • Use of anti-ulcer medications, antacid/acid suppression medications, gastroprokinetics, aspirin (>325 mg daily), other NSAIDs, antibiotics, and other medications that effect the GI system within 2 weeks prior to Screening. Must be able to stay off these medications during the study, except for proton pump inhibitors (PPIs) administered during the PPI Run-in Period.
  • Required use of concomitant medications known to adversely interact with other gastroprokinetic agents or proton pump inhibitors.
  • H. pylori eradication therapy (PPIs, antibiotics, bismuth preparations) in the 2 weeks prior to the upper endoscopy.
  • Treatment for H. pylori required during the study.
  • Subject has received an drug within 30 days or 10 half-lives, which ever is longer, or participated in more than 3 clinical studies within 12 months, prior to Visit 1.
  • Previous treatment with YM443.
  • Employees of the Yamanouchi Group or CROs involved in the study.
  • More than one subject per household to participate in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
416 participants (actual)

Interventions

06

Study locations

59 sites
  • Dr. Suresh Karne
    Huntsville, Alabama 35802, United States
  • James Thrasher, MD
    Little Rock, Arkansas 72205, United States
  • Dr. Dennis Riff
    Anaheim, California 92801, United States
  • Dr. Peter Winkle
    Cypress, California 90630, United States
  • Dr. Ramin Farsad
    Encinitas, California 92024, United States
  • Dr. Prahalad Jajodia
    Fresno, California 93703, United States
  • Dr. Gurmej Dhillon
    Fresno, California 93710, United States
  • Dr. Steven Duckor
    Orange, California 92869, United States
  • Dr. Theodor Feinstat
    Roseville, California 95661, United States
  • Scott Levenson, MD
    San Carlos, California 94070, United States
  • Dr. Michael Bennett
    San Diego, California 92123, United States
  • Dr. William Snape
    San Francisco, California 94115, United States
  • Dr. Abbass Shafii
    Colorado Springs, Colorado 80909, United States
  • Dr. Julio Salcedo
    Washington, District of Columbia 20010, United States
  • Dr. Daniel Maico
    Gainesville, Florida 32605, United States
  • Dr. Simon Behar
    Hialeah, Florida 33013, United States
  • Wayne Schonfeld, MD
    Hollywood, Florida 33021, United States
  • Dr. Stephen Palte
    Atlanta, Georgia 30339, United States
  • Dr. Nathan Segall
    Atlanta, Georgia 30342, United States
  • Azazuddin Ahmed, MD
    Oak Brook, Illinois 60523, United States
  • Brian Covey, MD
    Dubuque, Iowa 52001, United States
  • Dr. Richard McCallum
    Kansas City, Kansas 66160, United States
  • Robert Braun, MD
    Topeka, Kansas 66606, United States
  • Carroll Steinfeld, MD
    Madisonville, Kentucky 42431, United States
  • David Dulitz, MD
    Metairie, Louisiana 70006, United States
  • Dr. Bal Raj Bhandari
    Monroe, Louisiana 71201, United States
  • Dr. Robert Hardi
    Chevy Chase, Maryland 20815, United States
  • Dr. Braden Kuo
    Boston, Massachusetts 02114, United States
  • Dr. Robert Lustig
    Bridgewater, New Jersey 08807, United States
  • Dr. Rejendra Prasad Gupta
    Trenton, New Jersey 08618, United States
  • Dr. Vitaly Fishbein
    West Orange, New Jersey 07052, United States
  • Dr. Wieslaw Ignatowicz
    Brooklyn, New York 11222, United States
  • Dr. Eugene Bonapace
    Great Neck, New York 11021, United States
  • Dr. James Grendell
    Mineola, New York 11501, United States
  • Dr. William Harlan
    Asheville, North Carolina 28801, United States
  • Dr. John Poulos
    Fayetteville, North Carolina 28304, United States
  • Dr. Peter Eweje
    Jacksonville, North Carolina 28546, United States
  • Dr. Charles Barish
    Raleigh, North Carolina 27812, United States
  • Dr. William Gramley
    Wilmington, North Carolina 28401, United States
  • Dr. Robert Kindel
    Cincinnati, Ohio 45220, United States
  • Dr. Gregory Cooper
    Cleveland, Ohio 44106, United States
  • Dr. Gary Falk
    Cleveland, Ohio 44195, United States
  • Dr. Michael Grossman
    Oklahoma City, Oklahoma 73112, United States
  • Michael Mirhej, MD
    Eugene, Oregon 97401, United States
  • Dr. Nayan Shah
    Eynon, Pennsylvania 18403, United States
  • Dr. Robert Fisher
    Philadelphia, Pennsylvania 19140, United States
  • Dr. Cynthia Strout
    Mount Pleasant, South Carolina 29464, United States
  • Robert Smith, MD
    Saluda, South Carolina 29138, United States
  • Dr. Richard Krause
    Chattanooga, Tennessee 37404, United States
  • Dr. Mark Swaim
    Jackson, Tennessee 38305, United States
  • George James, MD
    Nashville, Tennessee 37203, United States
  • Dr. Ronald Pruitt
    Nashville, Tennessee 37205, United States
  • Dr. James Race
    Dallas, Texas 75224, United States
  • Sardar Khan, MD
    Houston, Texas 77090, United States
  • Ralph Alhalel, MD
    McAllen, Texas 78503, United States
  • Dr. Daniel Pambianco
    Charlottesville, Virginia 22911, United States
  • Dr. Mark Ringold
    Christiansburg, Virginia 24073, United States
  • Vinod Rustgi, MD
    Fairfax, Virginia 22031, United States
  • Dr. Michael Schmalz
    Milwaukee, Wisconsin 53215, United States
07

References and documents

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2004 to primary completion in Mar 2006, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2005
First posted
Jan 27, 2005
StartActual
Mar 10, 2004
Primary completionActual
Mar 11, 2006
CompletionActual
Mar 11, 2006
Last update
Jan 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00102310
Collaborators
Astellas Pharma US, Inc.
Responsible party
Sponsor
First posted
Jan 27, 2005
Start date
Mar 10, 2004
Primary completion
Mar 11, 2006
Completion
Mar 11, 2006
Last update
Jan 10, 2018

Study contacts

Medical Monitor
study director · APUS
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion